U.S. markets closed

Arrowhead Pharmaceuticals, Inc. (ARWR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
50.08+0.70 (+1.42%)
At close: 4:00PM EDT

50.08 0.00 (0.00%)
After hours: 4:53PM EDT

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard
Suite 700
Pasadena, CA 91105
United States
626-304-3400
http://arrowheadpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees134

Key Executives

NameTitlePayExercisedYear Born
Dr. Christopher R. AnzaloneCEO, Pres & Director2.22M3.72M1969
Mr. Kenneth A. MyszkowskiChief Financial Officer685.85k759.46k1966
Mr. Patrick O'BrienGen. Counsel & Corp. Sec.683.54kN/A1964
Dr. Bruce D. GivenAdvisor1.35M3.53M1954
Dr. Mark M. DavisFounder and Founder & Director of Insert Therapeutics Inc & CalandoN/AN/AN/A
Dr. Curt Bradshaw Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Jane DavidsonHead of HR & Admin., VP and Corp. Sec.N/AN/AN/A
Dr. Vincent AnzaloneVP of Investor RelationsN/AN/AN/A
Mr. Howard LovyDirector of CommunicationsN/AN/AN/A
Dr. James HamiltonHead of Clinical Devel. & VPN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD for treating liver diseases; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Corporate Governance

Arrowhead Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 4. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.